aMoon Fund
Description
aMoon Fund is a prominent Israeli-based venture capital firm dedicated to transforming healthcare through investments in disruptive healthtech and life sciences companies. Co-founded by Marius Nacht, co-founder of Check Point Software Technologies, and Dr. Yair Schindel, the firm leverages deep industry expertise and a global network to support its portfolio. aMoon's investment thesis centers on backing companies that are developing groundbreaking solutions in areas such as digital health, medical devices, biotechnology, and pharmaceuticals, aiming to bridge the gap between scientific innovation and commercial success.
The firm employs a hands-on approach, providing not only capital but also strategic guidance, operational support, and access to key opinion leaders and industry partners. While they invest across various stages, from seed to growth, their sweet spot often lies in leading or co-leading Series A and B rounds. aMoon seeks out companies with strong scientific foundations, clear market potential, and visionary leadership, focusing on long-term partnerships that can accelerate the development and adoption of life-changing technologies.
aMoon has demonstrated significant fundraising prowess, underscoring its capacity to make substantial investments. The firm successfully closed its third fund, aMoon III, at $750 million in 2022, following aMoon II which raised $660 million in 2019. This capital base, totaling over $1.6 billion across all funds, enables aMoon to deploy significant initial checks and provide robust follow-on funding to support its portfolio companies through critical growth phases. Their commitment to fostering innovation in healthcare positions them as a key player in the global healthtech investment landscape.
Investor Profile
aMoon Fund has backed more than 48 startups, with 6 new investments in the last 12 months alone. The firm has led 20 rounds, about 42% of its total and boasts 9 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B, Series C, Series Unknown rounds (top funding stages).
- Majority of deals are located in United States, Israel, Switzerland.
- Strong thematic focus on Health Care, Biotechnology, Medical.
- Led 2 rounds in the past year.
- Typical check size: $10M – $40M.
Stage Focus
- Series B (27%)
- Series C (17%)
- Series Unknown (17%)
- Series A (17%)
- Series D (8%)
- Series E (6%)
- Post Ipo Equity (2%)
- Series F (2%)
- Debt Financing (2%)
- Pre Seed (2%)
Country Focus
- United States (63%)
- Israel (33%)
- Switzerland (4%)
Industry Focus
- Health Care
- Biotechnology
- Medical
- Health Diagnostics
- Life Science
- Artificial Intelligence (Ai)
- Medical Device
- Analytics
- Therapeutics
- Genetics
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
